Tech Company Financing Transactions
Syntis Bio Funding Round
On 7/1/2025, Syntis Bio received $38 million in Series A financing from Cerberus Capital Management, Apollo Crypto and Bold Capital Partners.
Transaction Overview
Company Name
Announced On
7/1/2025
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
135 Morrissey Boulevard 101A
Boston, MA 02125
USA
Boston, MA 02125
USA
Phone
Website
Email Address
Overview
Our mission is to develop oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is revolutionizing oral therapy for obesity, diabetes and rare diseases by unlocking the full therapeutic potential of the small intestine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Dhanda
Browse more venture capital transactions:
Prev: 7/1/2025: Emerald AI venture capital transaction
Next: 7/1/2025: Bedrock Research venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs